Free Trial

Apollomics (APLMW) Competitors

$0.01
0.00 (0.00%)
(As of 05/20/2024 ET)

APLMW vs. ATNFW, SXTPW, DRTSW, ARTLW, BCDAW, BCTXW, CDIOW, CTCXW, SAVAW, and CELUW

Should you be buying Apollomics stock or one of its competitors? The main competitors of Apollomics include 180 Life Sciences (ATNFW), 60 Degrees Pharmaceuticals (SXTPW), Alpha Tau Medical (DRTSW), Artelo Biosciences (ARTLW), BioCardia (BCDAW), BriaCell Therapeutics (BCTXW), Cardio Diagnostics (CDIOW), Carmell (CTCXW), Cassava Sciences (SAVAW), and Celularity (CELUW). These companies are all part of the "biotechnology" industry.

Apollomics vs.

180 Life Sciences (NASDAQ:ATNFW) and Apollomics (NASDAQ:APLMW) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, community ranking, media sentiment, valuation and institutional ownership.

Company Net Margins Return on Equity Return on Assets
180 Life SciencesN/A N/A N/A
Apollomics N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
180 Life SciencesN/AN/AN/AN/AN/A
ApollomicsN/AN/AN/AN/AN/A

In the previous week, 180 Life Sciences had 1 more articles in the media than Apollomics. MarketBeat recorded 1 mentions for 180 Life Sciences and 0 mentions for Apollomics. Apollomics' average media sentiment score of 0.00 equaled 180 Life Sciences'average media sentiment score.

Company Overall Sentiment
180 Life Sciences Neutral
Apollomics Neutral

180 Life Sciences and Apollomics both received 0 outperform votes by MarketBeat users.

CompanyUnderperformOutperform
180 Life SciencesN/AN/A
ApollomicsN/AN/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
180 Life Sciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Apollomics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Summary

180 Life Sciences beats Apollomics on 1 of the 1 factors compared between the two stocks.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

APLMW vs. The Competition

MetricApollomicsBiotechnology IndustryMedical SectorNASDAQ Exchange
Market CapN/A$189.88M$5.05B$7.96B
Dividend YieldN/A3.42%44.98%3.91%
P/E RatioN/A244.01116.0914.29
Price / SalesN/A16,125.782,419.1378.73
Price / CashN/A11.2532.6629.27
Price / BookN/A6.215.034.50
Net IncomeN/A-$18.18M$103.33M$213.09M
7 Day PerformanceN/A0.25%1.03%1.20%
1 Month PerformanceN/A5.16%5.74%6.66%
1 Year PerformanceN/A5.89%7.32%9.73%

Apollomics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ATNFW
180 Life Sciences
0 of 5 stars
$0.01
flat
N/A-64.5%$0.00N/A0.004Positive News
Gap Up
SXTPW
60 Degrees Pharmaceuticals
0 of 5 stars
$0.08
-28.6%
N/AN/A$0.00$253,573.000.002Positive News
Gap Down
DRTSW
Alpha Tau Medical
0 of 5 stars
$0.23
flat
N/A-40.8%$0.00N/A0.00121News Coverage
Positive News
Gap Down
ARTLW
Artelo Biosciences
0 of 5 stars
$0.01
flat
N/AN/A$0.00N/A0.006Positive News
BCDAW
BioCardia
0 of 5 stars
$0.02
flat
N/A-98.2%$0.00$477,000.000.0016Positive News
BCTXW
BriaCell Therapeutics
0 of 5 stars
$0.90
+2.3%
N/A-81.3%$0.00N/A0.0016Gap Down
High Trading Volume
CDIOW
Cardio Diagnostics
0 of 5 stars
$0.05
-43.9%
N/A-49.9%$0.00$17,065.000.007Positive News
Gap Down
High Trading Volume
CTCXW
Carmell
0 of 5 stars
$0.08
-21.0%
N/AN/A$0.00$3.73M0.009Positive News
Gap Down
SAVAW
Cassava Sciences
0 of 5 stars
$0.03
flat
N/AN/A$0.00N/A0.0029Positive News
CELUW
Celularity
0 of 5 stars
$0.02
flat
N/A-51.0%$0.00$14.79M0.00225News Coverage
Gap Up

Related Companies and Tools

This page (NASDAQ:APLMW) was last updated on 5/21/2024 by MarketBeat.com Staff

From Our Partners